Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free N4P Stock Alerts

N4 Pharma (N4P) Competitors

N4 Pharma logo
GBX 0.68 0.00 (0.00%)
As of 05/18/2026
Compare

N4P vs. CHLL, MXC, RGT, CEL, and HELD

Should you buy N4 Pharma stock or one of its competitors? MarketBeat compares N4 Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with N4 Pharma include Chill Brands Group (CHLL), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), and Hellenic Dynamics (HELD). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does N4 Pharma compare to Chill Brands Group?

N4 Pharma (LON:N4P) and Chill Brands Group (LON:CHLL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

In the previous week, Chill Brands Group's average media sentiment score of 1.50 beat N4 Pharma's score of 0.00 indicating that Chill Brands Group is being referred to more favorably in the news media.

Company Overall Sentiment
N4 Pharma Neutral
Chill Brands Group Positive

N4 Pharma has a beta of -0.37, suggesting that its stock price is 137% less volatile than the broader market. Comparatively, Chill Brands Group has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

0.2% of N4 Pharma shares are held by institutional investors. Comparatively, 1.5% of Chill Brands Group shares are held by institutional investors. 22.0% of N4 Pharma shares are held by company insiders. Comparatively, 10.3% of Chill Brands Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Chill Brands Group has a net margin of 0.00% compared to N4 Pharma's net margin of -15,603.59%. N4 Pharma's return on equity of -91.34% beat Chill Brands Group's return on equity.

Company Net Margins Return on Equity Return on Assets
N4 Pharma-15,603.59% -91.34% -56.00%
Chill Brands Group N/A -2,802.21%-44.64%

N4 Pharma has higher earnings, but lower revenue than Chill Brands Group. N4 Pharma is trading at a lower price-to-earnings ratio than Chill Brands Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£7.07K800.95-£1.63M-£0.24N/A
Chill Brands Group£305.70K54.40-£3.64M-£6.50N/A

Summary

Chill Brands Group beats N4 Pharma on 7 of the 12 factors compared between the two stocks.

How does N4 Pharma compare to Argent BioPharma?

N4 Pharma (LON:N4P) and Argent BioPharma (LON:MXC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the broader market. Comparatively, Argent BioPharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

N4 Pharma has higher earnings, but lower revenue than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£7.07K800.95-£1.63M-£0.24N/A
Argent BioPharma£1.32M0.00-£17.02M-£1.66N/A

In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.

Company Overall Sentiment
N4 Pharma Neutral
Argent BioPharma Neutral

0.2% of N4 Pharma shares are held by institutional investors. Comparatively, 1.2% of Argent BioPharma shares are held by institutional investors. 22.0% of N4 Pharma shares are held by insiders. Comparatively, 8.2% of Argent BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Argent BioPharma has a net margin of 0.00% compared to N4 Pharma's net margin of -15,603.59%. Argent BioPharma's return on equity of 0.00% beat N4 Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
N4 Pharma-15,603.59% -91.34% -56.00%
Argent BioPharma N/A N/A -58.96%

Summary

N4 Pharma and Argent BioPharma tied by winning 5 of the 10 factors compared between the two stocks.

How does N4 Pharma compare to Argent BioPharma?

N4 Pharma (LON:N4P) and Argent BioPharma (LON:RGT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Argent BioPharma has a net margin of -1,967.38% compared to N4 Pharma's net margin of -15,603.59%. Argent BioPharma's return on equity of 279.26% beat N4 Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
N4 Pharma-15,603.59% -91.34% -56.00%
Argent BioPharma -1,967.38%279.26%-108.57%

In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score.

Company Overall Sentiment
N4 Pharma Neutral
Argent BioPharma Neutral

0.2% of N4 Pharma shares are owned by institutional investors. Comparatively, 1.1% of Argent BioPharma shares are owned by institutional investors. 22.0% of N4 Pharma shares are owned by company insiders. Comparatively, 17.8% of Argent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

N4 Pharma has a beta of -0.37, indicating that its share price is 137% less volatile than the broader market. Comparatively, Argent BioPharma has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

N4 Pharma has higher revenue and earnings than Argent BioPharma. N4 Pharma is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£7.07K800.95-£1.63M-£0.24N/A
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A

Summary

Argent BioPharma beats N4 Pharma on 5 of the 9 factors compared between the two stocks.

How does N4 Pharma compare to Celadon Pharmaceuticals?

N4 Pharma (LON:N4P) and Celadon Pharmaceuticals (LON:CEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

N4 Pharma has higher earnings, but lower revenue than Celadon Pharmaceuticals. N4 Pharma is trading at a lower price-to-earnings ratio than Celadon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£7.07K800.95-£1.63M-£0.24N/A
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A

In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Celadon Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
N4 Pharma Neutral
Celadon Pharmaceuticals Neutral

0.2% of N4 Pharma shares are held by institutional investors. Comparatively, 10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 22.0% of N4 Pharma shares are held by company insiders. Comparatively, 65.1% of Celadon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Celadon Pharmaceuticals has a net margin of -9,520.00% compared to N4 Pharma's net margin of -15,603.59%. N4 Pharma's return on equity of -91.34% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
N4 Pharma-15,603.59% -91.34% -56.00%
Celadon Pharmaceuticals -9,520.00%-131.82%-34.40%

N4 Pharma has a beta of -0.37, suggesting that its stock price is 137% less volatile than the broader market. Comparatively, Celadon Pharmaceuticals has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Summary

Celadon Pharmaceuticals beats N4 Pharma on 7 of the 11 factors compared between the two stocks.

How does N4 Pharma compare to Hellenic Dynamics?

N4 Pharma (LON:N4P) and Hellenic Dynamics (LON:HELD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Hellenic Dynamics'average media sentiment score.

Company Overall Sentiment
N4 Pharma Neutral
Hellenic Dynamics Neutral

N4 Pharma has higher revenue and earnings than Hellenic Dynamics. N4 Pharma is trading at a lower price-to-earnings ratio than Hellenic Dynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
N4 Pharma£7.07K800.95-£1.63M-£0.24N/A
Hellenic DynamicsN/AN/A-£5.22M-£3.55N/A

0.2% of N4 Pharma shares are owned by institutional investors. Comparatively, 0.1% of Hellenic Dynamics shares are owned by institutional investors. 22.0% of N4 Pharma shares are owned by insiders. Comparatively, 72.9% of Hellenic Dynamics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hellenic Dynamics has a net margin of 0.00% compared to N4 Pharma's net margin of -15,603.59%. N4 Pharma's return on equity of -91.34% beat Hellenic Dynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
N4 Pharma-15,603.59% -91.34% -56.00%
Hellenic Dynamics N/A -364.21%N/A

Summary

N4 Pharma beats Hellenic Dynamics on 5 of the 9 factors compared between the two stocks.

Get N4 Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding N4P and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

N4P vs. The Competition

Export
MetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£5.66M£2.43B£6.44B£2.77B
Dividend Yield3.12%2.95%2.69%6.12%
P/E Ratio-2.834.8523.77365.54
Price / Sales800.951,764.22488.5087,173.10
Price / Cash2.2510.1841.3927.85
Price / Book1.5210.829.767.68
Net Income-£1.63M£20.70B£3.56B£5.89B
7 Day PerformanceN/A0.54%-3.19%-0.55%
1 Month Performance18.26%7.31%-0.11%3.15%
1 Year Performance45.30%16.85%25.29%73.57%

N4 Pharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
N4P
N4 Pharma
N/AGBX 0.68
flat		N/A+36.0%£5.66M£7.07KN/A5
CHLL
Chill Brands Group
N/AGBX 3.50
+7.7%		N/AN/A£18.30M£305.70KN/A7
MXC
Argent BioPharma
N/AN/AN/AN/A£9.65M£1.32MN/A5
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat		N/AN/A£8.22M£123.38KN/A2,780

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:N4P) was last updated on 6/5/2026 by MarketBeat.com Staff.
From Our Partners
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel